nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—TEK—coronary artery disease	0.186	0.513	CbGaD
Ponatinib—KDR—coronary artery disease	0.091	0.251	CbGaD
Ponatinib—KIT—coronary artery disease	0.0859	0.237	CbGaD
Ponatinib—ABCB11—Rosuvastatin—coronary artery disease	0.0217	0.0623	CbGbCtD
Ponatinib—ABCB11—Pravastatin—coronary artery disease	0.0198	0.0567	CbGbCtD
Ponatinib—ABCG2—Pitavastatin—coronary artery disease	0.014	0.0402	CbGbCtD
Ponatinib—ABCG2—Telmisartan—coronary artery disease	0.014	0.0402	CbGbCtD
Ponatinib—CYP2C8—Fenofibrate—coronary artery disease	0.0123	0.0353	CbGbCtD
Ponatinib—ABCG2—Rosuvastatin—coronary artery disease	0.0103	0.0296	CbGbCtD
Ponatinib—ABCG2—Ezetimibe—coronary artery disease	0.0103	0.0296	CbGbCtD
Ponatinib—CYP2C8—Gemfibrozil—coronary artery disease	0.00985	0.0283	CbGbCtD
Ponatinib—ABCG2—Pravastatin—coronary artery disease	0.0094	0.027	CbGbCtD
Ponatinib—ABCB1—Ticagrelor—coronary artery disease	0.00936	0.0268	CbGbCtD
Ponatinib—CYP3A5—Clopidogrel—coronary artery disease	0.00888	0.0255	CbGbCtD
Ponatinib—CYP2C8—Clopidogrel—coronary artery disease	0.00854	0.0245	CbGbCtD
Ponatinib—CYP3A5—Eplerenone—coronary artery disease	0.00826	0.0237	CbGbCtD
Ponatinib—CYP2C8—Pitavastatin—coronary artery disease	0.00746	0.0214	CbGbCtD
Ponatinib—ABCB1—Perindopril—coronary artery disease	0.00578	0.0166	CbGbCtD
Ponatinib—ABCB1—Clopidogrel—coronary artery disease	0.00578	0.0166	CbGbCtD
Ponatinib—CYP3A5—Rosuvastatin—coronary artery disease	0.00572	0.0164	CbGbCtD
Ponatinib—CYP3A4—Ticagrelor—coronary artery disease	0.00561	0.0161	CbGbCtD
Ponatinib—CYP2C8—Acetylsalicylic acid—coronary artery disease	0.00536	0.0154	CbGbCtD
Ponatinib—CYP3A5—Simvastatin—coronary artery disease	0.00532	0.0153	CbGbCtD
Ponatinib—CYP3A5—Lovastatin—coronary artery disease	0.00521	0.0149	CbGbCtD
Ponatinib—CYP3A5—Pravastatin—coronary artery disease	0.00521	0.0149	CbGbCtD
Ponatinib—CYP2C8—Simvastatin—coronary artery disease	0.00512	0.0147	CbGbCtD
Ponatinib—ABCB1—Pitavastatin—coronary artery disease	0.00505	0.0145	CbGbCtD
Ponatinib—ABCB1—Telmisartan—coronary artery disease	0.00505	0.0145	CbGbCtD
Ponatinib—CYP2C8—Pravastatin—coronary artery disease	0.00501	0.0144	CbGbCtD
Ponatinib—CYP2C8—Lovastatin—coronary artery disease	0.00501	0.0144	CbGbCtD
Ponatinib—CYP3A4—Fenofibrate—coronary artery disease	0.005	0.0143	CbGbCtD
Ponatinib—ABCB1—Enalapril—coronary artery disease	0.00479	0.0137	CbGbCtD
Ponatinib—ABCB1—Lisinopril—coronary artery disease	0.00479	0.0137	CbGbCtD
Ponatinib—CYP3A5—Atorvastatin—coronary artery disease	0.00474	0.0136	CbGbCtD
Ponatinib—CYP2C8—Atorvastatin—coronary artery disease	0.00456	0.0131	CbGbCtD
Ponatinib—CYP3A5—Losartan—coronary artery disease	0.00434	0.0124	CbGbCtD
Ponatinib—CYP2C8—Losartan—coronary artery disease	0.00417	0.012	CbGbCtD
Ponatinib—CYP2D6—Niacin—coronary artery disease	0.00413	0.0118	CbGbCtD
Ponatinib—ABCB1—Timolol—coronary artery disease	0.00407	0.0117	CbGbCtD
Ponatinib—CYP3A4—Gemfibrozil—coronary artery disease	0.00399	0.0115	CbGbCtD
Ponatinib—CYP2D6—Timolol—coronary artery disease	0.00384	0.011	CbGbCtD
Ponatinib—ABCB1—Ezetimibe—coronary artery disease	0.00372	0.0107	CbGbCtD
Ponatinib—ABCB1—Acetylsalicylic acid—coronary artery disease	0.00363	0.0104	CbGbCtD
Ponatinib—ABCB1—Captopril—coronary artery disease	0.00359	0.0103	CbGbCtD
Ponatinib—CYP3A4—Clopidogrel—coronary artery disease	0.00346	0.00994	CbGbCtD
Ponatinib—ABCB1—Simvastatin—coronary artery disease	0.00346	0.00994	CbGbCtD
Ponatinib—ABCB1—Lovastatin—coronary artery disease	0.00339	0.00972	CbGbCtD
Ponatinib—ABCB1—Pravastatin—coronary artery disease	0.00339	0.00972	CbGbCtD
Ponatinib—CYP2D6—Captopril—coronary artery disease	0.00338	0.00969	CbGbCtD
Ponatinib—CYP2D6—Simvastatin—coronary artery disease	0.00326	0.00936	CbGbCtD
Ponatinib—CYP3A4—Eplerenone—coronary artery disease	0.00322	0.00924	CbGbCtD
Ponatinib—CYP2D6—Pravastatin—coronary artery disease	0.00319	0.00916	CbGbCtD
Ponatinib—CYP2D6—Lovastatin—coronary artery disease	0.00319	0.00916	CbGbCtD
Ponatinib—ABCB1—Atorvastatin—coronary artery disease	0.00309	0.00886	CbGbCtD
Ponatinib—CYP2D6—Atorvastatin—coronary artery disease	0.00291	0.00834	CbGbCtD
Ponatinib—CYP3A4—Enalapril—coronary artery disease	0.00287	0.00823	CbGbCtD
Ponatinib—ABCB1—Losartan—coronary artery disease	0.00282	0.0081	CbGbCtD
Ponatinib—RET—autonomic nervous system—coronary artery disease	0.00253	0.0701	CbGeAlD
Ponatinib—CYP3A4—Ezetimibe—coronary artery disease	0.00223	0.0064	CbGbCtD
Ponatinib—CYP3A4—Rosuvastatin—coronary artery disease	0.00223	0.0064	CbGbCtD
Ponatinib—CYP3A4—Simvastatin—coronary artery disease	0.00207	0.00595	CbGbCtD
Ponatinib—CYP3A4—Pravastatin—coronary artery disease	0.00203	0.00583	CbGbCtD
Ponatinib—CYP3A4—Lovastatin—coronary artery disease	0.00203	0.00583	CbGbCtD
Ponatinib—CYP3A4—Atorvastatin—coronary artery disease	0.00185	0.00531	CbGbCtD
Ponatinib—CYP3A4—Losartan—coronary artery disease	0.00169	0.00485	CbGbCtD
Ponatinib—TEK—artery—coronary artery disease	0.00131	0.0362	CbGeAlD
Ponatinib—SRC—artery—coronary artery disease	0.00116	0.0322	CbGeAlD
Ponatinib—FGFR4—heart—coronary artery disease	0.00113	0.0311	CbGeAlD
Ponatinib—TEK—endothelium—coronary artery disease	0.00111	0.0306	CbGeAlD
Ponatinib—KDR—artery—coronary artery disease	0.00107	0.0296	CbGeAlD
Ponatinib—BCR—cardiac ventricle—coronary artery disease	0.00101	0.028	CbGeAlD
Ponatinib—SRC—endothelium—coronary artery disease	0.000982	0.0272	CbGeAlD
Ponatinib—Nilotinib—MAPK14—coronary artery disease	0.000971	0.342	CrCbGaD
Ponatinib—BCR—myocardium—coronary artery disease	0.000952	0.0263	CbGeAlD
Ponatinib—KDR—endothelium—coronary artery disease	0.000903	0.025	CbGeAlD
Ponatinib—Nilotinib—TEK—coronary artery disease	0.000888	0.313	CrCbGaD
Ponatinib—FGFR1—myocardium—coronary artery disease	0.000847	0.0234	CbGeAlD
Ponatinib—FGFR4—blood—coronary artery disease	0.00084	0.0232	CbGeAlD
Ponatinib—KIT—endothelium—coronary artery disease	0.0008	0.0221	CbGeAlD
Ponatinib—FGFR3—heart—coronary artery disease	0.000768	0.0212	CbGeAlD
Ponatinib—TEK—cardiac ventricle—coronary artery disease	0.000734	0.0203	CbGeAlD
Ponatinib—TEK—myocardium—coronary artery disease	0.00069	0.0191	CbGeAlD
Ponatinib—BCR—heart—coronary artery disease	0.000664	0.0184	CbGeAlD
Ponatinib—FLT3—heart—coronary artery disease	0.00066	0.0183	CbGeAlD
Ponatinib—FLT3—cardiovascular system—coronary artery disease	0.000622	0.0172	CbGeAlD
Ponatinib—KDR—cardiac ventricle—coronary artery disease	0.0006	0.0166	CbGeAlD
Ponatinib—FGFR1—heart—coronary artery disease	0.000591	0.0164	CbGeAlD
Ponatinib—LYN—blood—coronary artery disease	0.000576	0.0159	CbGeAlD
Ponatinib—BCR—cardiac atrium—coronary artery disease	0.000568	0.0157	CbGeAlD
Ponatinib—KDR—myocardium—coronary artery disease	0.000564	0.0156	CbGeAlD
Ponatinib—RET—heart—coronary artery disease	0.000529	0.0146	CbGeAlD
Ponatinib—LCK—heart—coronary artery disease	0.000529	0.0146	CbGeAlD
Ponatinib—FGFR1—cardiac atrium—coronary artery disease	0.000505	0.014	CbGeAlD
Ponatinib—KIT—myocardium—coronary artery disease	0.0005	0.0138	CbGeAlD
Ponatinib—BCR—blood—coronary artery disease	0.000496	0.0137	CbGeAlD
Ponatinib—FLT3—blood—coronary artery disease	0.000492	0.0136	CbGeAlD
Ponatinib—TEK—heart—coronary artery disease	0.000482	0.0133	CbGeAlD
Ponatinib—FGFR2—cardiovascular system—coronary artery disease	0.000474	0.0131	CbGeAlD
Ponatinib—ABL1—cardiac ventricle—coronary artery disease	0.000463	0.0128	CbGeAlD
Ponatinib—TEK—cardiovascular system—coronary artery disease	0.000455	0.0126	CbGeAlD
Ponatinib—PDGFRA—heart—coronary artery disease	0.000437	0.0121	CbGeAlD
Ponatinib—ABL1—myocardium—coronary artery disease	0.000435	0.012	CbGeAlD
Ponatinib—SRC—heart—coronary artery disease	0.000428	0.0118	CbGeAlD
Ponatinib—TEK—cardiac atrium—coronary artery disease	0.000412	0.0114	CbGeAlD
Ponatinib—PDGFRA—cardiovascular system—coronary artery disease	0.000412	0.0114	CbGeAlD
Ponatinib—Nilotinib—KIT—coronary artery disease	0.000409	0.144	CrCbGaD
Ponatinib—SRC—cardiovascular system—coronary artery disease	0.000404	0.0112	CbGeAlD
Ponatinib—RET—blood—coronary artery disease	0.000395	0.0109	CbGeAlD
Ponatinib—LCK—blood—coronary artery disease	0.000395	0.0109	CbGeAlD
Ponatinib—KDR—heart—coronary artery disease	0.000394	0.0109	CbGeAlD
Ponatinib—FGFR2—blood—coronary artery disease	0.000375	0.0104	CbGeAlD
Ponatinib—KDR—cardiovascular system—coronary artery disease	0.000372	0.0103	CbGeAlD
Ponatinib—SRC—cardiac atrium—coronary artery disease	0.000366	0.0101	CbGeAlD
Ponatinib—TEK—blood—coronary artery disease	0.00036	0.00995	CbGeAlD
Ponatinib—KIT—heart—coronary artery disease	0.000349	0.00966	CbGeAlD
Ponatinib—Imatinib—KIT—coronary artery disease	0.000341	0.12	CrCbGaD
Ponatinib—KDR—cardiac atrium—coronary artery disease	0.000337	0.00932	CbGeAlD
Ponatinib—KIT—cardiovascular system—coronary artery disease	0.000329	0.00911	CbGeAlD
Ponatinib—PDGFRA—blood—coronary artery disease	0.000326	0.00901	CbGeAlD
Ponatinib—SRC—blood—coronary artery disease	0.000319	0.00884	CbGeAlD
Ponatinib—ABL1—heart—coronary artery disease	0.000304	0.00841	CbGeAlD
Ponatinib—KDR—blood—coronary artery disease	0.000294	0.00813	CbGeAlD
Ponatinib—ABL1—cardiovascular system—coronary artery disease	0.000287	0.00793	CbGeAlD
Ponatinib—KIT—blood—coronary artery disease	0.00026	0.00721	CbGeAlD
Ponatinib—ABL1—cardiac atrium—coronary artery disease	0.00026	0.00719	CbGeAlD
Ponatinib—ABL1—blood—coronary artery disease	0.000227	0.00627	CbGeAlD
Ponatinib—ABCG2—heart—coronary artery disease	0.000192	0.0053	CbGeAlD
Ponatinib—Imatinib—CYP2C19—coronary artery disease	0.000149	0.0523	CrCbGaD
Ponatinib—CYP2C8—blood—coronary artery disease	0.000147	0.00407	CbGeAlD
Ponatinib—ABCG2—blood—coronary artery disease	0.000143	0.00396	CbGeAlD
Ponatinib—CYP3A5—blood—coronary artery disease	0.000133	0.00367	CbGeAlD
Ponatinib—CYP3A4—blood—coronary artery disease	9.96e-05	0.00276	CbGeAlD
Ponatinib—CYP2D6—blood—coronary artery disease	9.8e-05	0.00271	CbGeAlD
Ponatinib—ABCB1—heart—coronary artery disease	9.45e-05	0.00261	CbGeAlD
Ponatinib—ABCB1—cardiovascular system—coronary artery disease	8.91e-05	0.00247	CbGeAlD
Ponatinib—Imatinib—ALB—coronary artery disease	8.24e-05	0.029	CrCbGaD
Ponatinib—ABCB1—blood—coronary artery disease	7.05e-05	0.00195	CbGeAlD
Ponatinib—Vision blurred—Lisinopril—coronary artery disease	3.95e-05	0.000319	CcSEcCtD
Ponatinib—Paraesthesia—Losartan—coronary artery disease	3.95e-05	0.000319	CcSEcCtD
Ponatinib—Gastrointestinal pain—Captopril—coronary artery disease	3.95e-05	0.000319	CcSEcCtD
Ponatinib—Cough—Timolol—coronary artery disease	3.94e-05	0.000319	CcSEcCtD
Ponatinib—Vomiting—Clopidogrel—coronary artery disease	3.94e-05	0.000319	CcSEcCtD
Ponatinib—Diarrhoea—Simvastatin—coronary artery disease	3.94e-05	0.000319	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Furosemide—coronary artery disease	3.93e-05	0.000318	CcSEcCtD
Ponatinib—Myalgia—Ramipril—coronary artery disease	3.93e-05	0.000318	CcSEcCtD
Ponatinib—Arthralgia—Ramipril—coronary artery disease	3.93e-05	0.000318	CcSEcCtD
Ponatinib—Fatigue—Furosemide—coronary artery disease	3.93e-05	0.000318	CcSEcCtD
Ponatinib—Abdominal pain—Telmisartan—coronary artery disease	3.92e-05	0.000317	CcSEcCtD
Ponatinib—Body temperature increased—Telmisartan—coronary artery disease	3.92e-05	0.000317	CcSEcCtD
Ponatinib—Dyspnoea—Losartan—coronary artery disease	3.92e-05	0.000317	CcSEcCtD
Ponatinib—Vomiting—Lovastatin—coronary artery disease	3.91e-05	0.000317	CcSEcCtD
Ponatinib—Dizziness—Eplerenone—coronary artery disease	3.91e-05	0.000316	CcSEcCtD
Ponatinib—Rash—Clopidogrel—coronary artery disease	3.91e-05	0.000316	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Ramipril—coronary artery disease	3.9e-05	0.000316	CcSEcCtD
Ponatinib—Dermatitis—Clopidogrel—coronary artery disease	3.9e-05	0.000316	CcSEcCtD
Ponatinib—Asthenia—Valsartan—coronary artery disease	3.9e-05	0.000315	CcSEcCtD
Ponatinib—Hypertension—Timolol—coronary artery disease	3.9e-05	0.000315	CcSEcCtD
Ponatinib—Pain—Furosemide—coronary artery disease	3.9e-05	0.000315	CcSEcCtD
Ponatinib—Constipation—Furosemide—coronary artery disease	3.9e-05	0.000315	CcSEcCtD
Ponatinib—Asthenia—Olmesartan—coronary artery disease	3.88e-05	0.000314	CcSEcCtD
Ponatinib—Headache—Clopidogrel—coronary artery disease	3.88e-05	0.000314	CcSEcCtD
Ponatinib—Rash—Lovastatin—coronary artery disease	3.88e-05	0.000314	CcSEcCtD
Ponatinib—Dermatitis—Lovastatin—coronary artery disease	3.88e-05	0.000314	CcSEcCtD
Ponatinib—Anaemia—Lisinopril—coronary artery disease	3.87e-05	0.000313	CcSEcCtD
Ponatinib—Dyspepsia—Losartan—coronary artery disease	3.87e-05	0.000313	CcSEcCtD
Ponatinib—Headache—Lovastatin—coronary artery disease	3.85e-05	0.000312	CcSEcCtD
Ponatinib—Pruritus—Valsartan—coronary artery disease	3.84e-05	0.000311	CcSEcCtD
Ponatinib—Dry mouth—Ramipril—coronary artery disease	3.84e-05	0.000311	CcSEcCtD
Ponatinib—Myalgia—Timolol—coronary artery disease	3.84e-05	0.000311	CcSEcCtD
Ponatinib—Arthralgia—Timolol—coronary artery disease	3.84e-05	0.000311	CcSEcCtD
Ponatinib—Vomiting—Ezetimibe—coronary artery disease	3.84e-05	0.00031	CcSEcCtD
Ponatinib—Gastrointestinal pain—Perindopril—coronary artery disease	3.83e-05	0.00031	CcSEcCtD
Ponatinib—Pruritus—Olmesartan—coronary artery disease	3.83e-05	0.00031	CcSEcCtD
Ponatinib—Decreased appetite—Losartan—coronary artery disease	3.82e-05	0.000309	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Timolol—coronary artery disease	3.82e-05	0.000309	CcSEcCtD
Ponatinib—Body temperature increased—Captopril—coronary artery disease	3.82e-05	0.000309	CcSEcCtD
Ponatinib—Abdominal pain—Captopril—coronary artery disease	3.82e-05	0.000309	CcSEcCtD
Ponatinib—Dizziness—Simvastatin—coronary artery disease	3.81e-05	0.000308	CcSEcCtD
Ponatinib—Rash—Ezetimibe—coronary artery disease	3.8e-05	0.000308	CcSEcCtD
Ponatinib—Dermatitis—Ezetimibe—coronary artery disease	3.8e-05	0.000308	CcSEcCtD
Ponatinib—Asthenia—Niacin—coronary artery disease	3.79e-05	0.000307	CcSEcCtD
Ponatinib—Fatigue—Losartan—coronary artery disease	3.79e-05	0.000307	CcSEcCtD
Ponatinib—Headache—Ezetimibe—coronary artery disease	3.78e-05	0.000306	CcSEcCtD
Ponatinib—Oedema—Ramipril—coronary artery disease	3.77e-05	0.000305	CcSEcCtD
Ponatinib—Dry mouth—Timolol—coronary artery disease	3.76e-05	0.000304	CcSEcCtD
Ponatinib—Constipation—Losartan—coronary artery disease	3.76e-05	0.000304	CcSEcCtD
Ponatinib—Pain—Losartan—coronary artery disease	3.76e-05	0.000304	CcSEcCtD
Ponatinib—Vomiting—Eplerenone—coronary artery disease	3.76e-05	0.000304	CcSEcCtD
Ponatinib—Leukopenia—Lisinopril—coronary artery disease	3.75e-05	0.000303	CcSEcCtD
Ponatinib—Nausea—Fenofibrate—coronary artery disease	3.74e-05	0.000303	CcSEcCtD
Ponatinib—Pruritus—Niacin—coronary artery disease	3.74e-05	0.000302	CcSEcCtD
Ponatinib—Asthenia—Pravastatin—coronary artery disease	3.73e-05	0.000302	CcSEcCtD
Ponatinib—Gastrointestinal pain—Furosemide—coronary artery disease	3.72e-05	0.000301	CcSEcCtD
Ponatinib—Rash—Eplerenone—coronary artery disease	3.72e-05	0.000301	CcSEcCtD
Ponatinib—Dermatitis—Eplerenone—coronary artery disease	3.72e-05	0.000301	CcSEcCtD
Ponatinib—Diarrhoea—Valsartan—coronary artery disease	3.72e-05	0.000301	CcSEcCtD
Ponatinib—Abdominal pain—Perindopril—coronary artery disease	3.7e-05	0.0003	CcSEcCtD
Ponatinib—Body temperature increased—Perindopril—coronary artery disease	3.7e-05	0.0003	CcSEcCtD
Ponatinib—Diarrhoea—Olmesartan—coronary artery disease	3.7e-05	0.000299	CcSEcCtD
Ponatinib—Headache—Eplerenone—coronary artery disease	3.7e-05	0.000299	CcSEcCtD
Ponatinib—Nervous system disorder—Ramipril—coronary artery disease	3.7e-05	0.000299	CcSEcCtD
Ponatinib—Thrombocytopenia—Ramipril—coronary artery disease	3.69e-05	0.000299	CcSEcCtD
Ponatinib—Oedema—Timolol—coronary artery disease	3.68e-05	0.000298	CcSEcCtD
Ponatinib—Pruritus—Pravastatin—coronary artery disease	3.68e-05	0.000298	CcSEcCtD
Ponatinib—Nausea—Clopidogrel—coronary artery disease	3.68e-05	0.000298	CcSEcCtD
Ponatinib—Skin disorder—Ramipril—coronary artery disease	3.66e-05	0.000296	CcSEcCtD
Ponatinib—Infection—Timolol—coronary artery disease	3.66e-05	0.000296	CcSEcCtD
Ponatinib—Vomiting—Simvastatin—coronary artery disease	3.66e-05	0.000296	CcSEcCtD
Ponatinib—Cough—Lisinopril—coronary artery disease	3.65e-05	0.000296	CcSEcCtD
Ponatinib—Nausea—Lovastatin—coronary artery disease	3.65e-05	0.000296	CcSEcCtD
Ponatinib—Hyperhidrosis—Ramipril—coronary artery disease	3.64e-05	0.000295	CcSEcCtD
Ponatinib—Rash—Simvastatin—coronary artery disease	3.63e-05	0.000294	CcSEcCtD
Ponatinib—Dermatitis—Simvastatin—coronary artery disease	3.63e-05	0.000293	CcSEcCtD
Ponatinib—Asthenia—Trandolapril—coronary artery disease	3.62e-05	0.000293	CcSEcCtD
Ponatinib—Diarrhoea—Niacin—coronary artery disease	3.62e-05	0.000293	CcSEcCtD
Ponatinib—Nervous system disorder—Timolol—coronary artery disease	3.61e-05	0.000292	CcSEcCtD
Ponatinib—Asthenia—Enalapril—coronary artery disease	3.61e-05	0.000292	CcSEcCtD
Ponatinib—Headache—Simvastatin—coronary artery disease	3.61e-05	0.000292	CcSEcCtD
Ponatinib—Abdominal pain—Furosemide—coronary artery disease	3.6e-05	0.000291	CcSEcCtD
Ponatinib—Body temperature increased—Furosemide—coronary artery disease	3.6e-05	0.000291	CcSEcCtD
Ponatinib—Gastrointestinal pain—Losartan—coronary artery disease	3.59e-05	0.000291	CcSEcCtD
Ponatinib—Dizziness—Valsartan—coronary artery disease	3.59e-05	0.000291	CcSEcCtD
Ponatinib—Nausea—Ezetimibe—coronary artery disease	3.58e-05	0.00029	CcSEcCtD
Ponatinib—Skin disorder—Timolol—coronary artery disease	3.58e-05	0.00029	CcSEcCtD
Ponatinib—Dizziness—Olmesartan—coronary artery disease	3.58e-05	0.000289	CcSEcCtD
Ponatinib—Pruritus—Trandolapril—coronary artery disease	3.57e-05	0.000289	CcSEcCtD
Ponatinib—Myalgia—Lisinopril—coronary artery disease	3.57e-05	0.000288	CcSEcCtD
Ponatinib—Arthralgia—Lisinopril—coronary artery disease	3.57e-05	0.000288	CcSEcCtD
Ponatinib—Hyperhidrosis—Timolol—coronary artery disease	3.56e-05	0.000288	CcSEcCtD
Ponatinib—Asthenia—Telmisartan—coronary artery disease	3.56e-05	0.000288	CcSEcCtD
Ponatinib—Pruritus—Enalapril—coronary artery disease	3.56e-05	0.000288	CcSEcCtD
Ponatinib—Diarrhoea—Pravastatin—coronary artery disease	3.56e-05	0.000288	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—coronary artery disease	3.54e-05	0.000286	CcSEcCtD
Ponatinib—Pruritus—Telmisartan—coronary artery disease	3.51e-05	0.000284	CcSEcCtD
Ponatinib—Nausea—Eplerenone—coronary artery disease	3.51e-05	0.000284	CcSEcCtD
Ponatinib—Dizziness—Niacin—coronary artery disease	3.49e-05	0.000283	CcSEcCtD
Ponatinib—Dry mouth—Lisinopril—coronary artery disease	3.49e-05	0.000282	CcSEcCtD
Ponatinib—Body temperature increased—Losartan—coronary artery disease	3.47e-05	0.000281	CcSEcCtD
Ponatinib—Abdominal pain—Losartan—coronary artery disease	3.47e-05	0.000281	CcSEcCtD
Ponatinib—Asthenia—Captopril—coronary artery disease	3.46e-05	0.00028	CcSEcCtD
Ponatinib—Diarrhoea—Trandolapril—coronary artery disease	3.46e-05	0.00028	CcSEcCtD
Ponatinib—Vomiting—Valsartan—coronary artery disease	3.46e-05	0.00028	CcSEcCtD
Ponatinib—Diarrhoea—Enalapril—coronary artery disease	3.44e-05	0.000279	CcSEcCtD
Ponatinib—Dizziness—Pravastatin—coronary artery disease	3.44e-05	0.000278	CcSEcCtD
Ponatinib—Vomiting—Olmesartan—coronary artery disease	3.44e-05	0.000278	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Ramipril—coronary artery disease	3.43e-05	0.000278	CcSEcCtD
Ponatinib—Rash—Valsartan—coronary artery disease	3.43e-05	0.000277	CcSEcCtD
Ponatinib—Dermatitis—Valsartan—coronary artery disease	3.42e-05	0.000277	CcSEcCtD
Ponatinib—Nausea—Simvastatin—coronary artery disease	3.42e-05	0.000277	CcSEcCtD
Ponatinib—Oedema—Lisinopril—coronary artery disease	3.42e-05	0.000277	CcSEcCtD
Ponatinib—Pruritus—Captopril—coronary artery disease	3.41e-05	0.000276	CcSEcCtD
Ponatinib—Rash—Olmesartan—coronary artery disease	3.41e-05	0.000276	CcSEcCtD
Ponatinib—Insomnia—Ramipril—coronary artery disease	3.41e-05	0.000276	CcSEcCtD
Ponatinib—Dermatitis—Olmesartan—coronary artery disease	3.41e-05	0.000276	CcSEcCtD
Ponatinib—Headache—Valsartan—coronary artery disease	3.4e-05	0.000275	CcSEcCtD
Ponatinib—Diarrhoea—Telmisartan—coronary artery disease	3.4e-05	0.000275	CcSEcCtD
Ponatinib—Infection—Lisinopril—coronary artery disease	3.4e-05	0.000275	CcSEcCtD
Ponatinib—Headache—Olmesartan—coronary artery disease	3.39e-05	0.000274	CcSEcCtD
Ponatinib—Paraesthesia—Ramipril—coronary artery disease	3.38e-05	0.000274	CcSEcCtD
Ponatinib—Asthenia—Perindopril—coronary artery disease	3.36e-05	0.000272	CcSEcCtD
Ponatinib—Dyspnoea—Ramipril—coronary artery disease	3.36e-05	0.000272	CcSEcCtD
Ponatinib—Vomiting—Niacin—coronary artery disease	3.36e-05	0.000272	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Timolol—coronary artery disease	3.36e-05	0.000272	CcSEcCtD
Ponatinib—Thrombocytopenia—Lisinopril—coronary artery disease	3.35e-05	0.000271	CcSEcCtD
Ponatinib—Dizziness—Trandolapril—coronary artery disease	3.34e-05	0.00027	CcSEcCtD
Ponatinib—Insomnia—Timolol—coronary artery disease	3.33e-05	0.00027	CcSEcCtD
Ponatinib—Rash—Niacin—coronary artery disease	3.33e-05	0.00027	CcSEcCtD
Ponatinib—Dermatitis—Niacin—coronary artery disease	3.33e-05	0.000269	CcSEcCtD
Ponatinib—Dizziness—Enalapril—coronary artery disease	3.33e-05	0.000269	CcSEcCtD
Ponatinib—Skin disorder—Lisinopril—coronary artery disease	3.32e-05	0.000269	CcSEcCtD
Ponatinib—Dyspepsia—Ramipril—coronary artery disease	3.32e-05	0.000268	CcSEcCtD
Ponatinib—Pruritus—Perindopril—coronary artery disease	3.32e-05	0.000268	CcSEcCtD
Ponatinib—Headache—Niacin—coronary artery disease	3.31e-05	0.000268	CcSEcCtD
Ponatinib—Paraesthesia—Timolol—coronary artery disease	3.31e-05	0.000268	CcSEcCtD
Ponatinib—Vomiting—Pravastatin—coronary artery disease	3.31e-05	0.000268	CcSEcCtD
Ponatinib—Hyperhidrosis—Lisinopril—coronary artery disease	3.3e-05	0.000267	CcSEcCtD
Ponatinib—Diarrhoea—Captopril—coronary artery disease	3.3e-05	0.000267	CcSEcCtD
Ponatinib—Dyspnoea—Timolol—coronary artery disease	3.28e-05	0.000266	CcSEcCtD
Ponatinib—Dizziness—Telmisartan—coronary artery disease	3.28e-05	0.000266	CcSEcCtD
Ponatinib—Rash—Pravastatin—coronary artery disease	3.28e-05	0.000265	CcSEcCtD
Ponatinib—Dermatitis—Pravastatin—coronary artery disease	3.28e-05	0.000265	CcSEcCtD
Ponatinib—Decreased appetite—Ramipril—coronary artery disease	3.28e-05	0.000265	CcSEcCtD
Ponatinib—Asthenia—Furosemide—coronary artery disease	3.27e-05	0.000264	CcSEcCtD
Ponatinib—Headache—Pravastatin—coronary artery disease	3.26e-05	0.000264	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Ramipril—coronary artery disease	3.25e-05	0.000263	CcSEcCtD
Ponatinib—Fatigue—Ramipril—coronary artery disease	3.25e-05	0.000263	CcSEcCtD
Ponatinib—Dyspepsia—Timolol—coronary artery disease	3.24e-05	0.000262	CcSEcCtD
Ponatinib—Nausea—Valsartan—coronary artery disease	3.23e-05	0.000261	CcSEcCtD
Ponatinib—Pruritus—Furosemide—coronary artery disease	3.22e-05	0.000261	CcSEcCtD
Ponatinib—Constipation—Ramipril—coronary artery disease	3.22e-05	0.000261	CcSEcCtD
Ponatinib—Nausea—Olmesartan—coronary artery disease	3.21e-05	0.00026	CcSEcCtD
Ponatinib—Vomiting—Trandolapril—coronary artery disease	3.21e-05	0.00026	CcSEcCtD
Ponatinib—Diarrhoea—Perindopril—coronary artery disease	3.21e-05	0.000259	CcSEcCtD
Ponatinib—Decreased appetite—Timolol—coronary artery disease	3.2e-05	0.000259	CcSEcCtD
Ponatinib—Vomiting—Enalapril—coronary artery disease	3.2e-05	0.000259	CcSEcCtD
Ponatinib—Dizziness—Captopril—coronary artery disease	3.19e-05	0.000258	CcSEcCtD
Ponatinib—Rash—Trandolapril—coronary artery disease	3.19e-05	0.000258	CcSEcCtD
Ponatinib—Dermatitis—Trandolapril—coronary artery disease	3.18e-05	0.000258	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Timolol—coronary artery disease	3.18e-05	0.000257	CcSEcCtD
Ponatinib—Fatigue—Timolol—coronary artery disease	3.18e-05	0.000257	CcSEcCtD
Ponatinib—Rash—Enalapril—coronary artery disease	3.17e-05	0.000257	CcSEcCtD
Ponatinib—Dermatitis—Enalapril—coronary artery disease	3.17e-05	0.000256	CcSEcCtD
Ponatinib—Headache—Trandolapril—coronary artery disease	3.17e-05	0.000256	CcSEcCtD
Ponatinib—Vomiting—Telmisartan—coronary artery disease	3.16e-05	0.000255	CcSEcCtD
Ponatinib—Asthenia—Losartan—coronary artery disease	3.15e-05	0.000255	CcSEcCtD
Ponatinib—Headache—Enalapril—coronary artery disease	3.15e-05	0.000255	CcSEcCtD
Ponatinib—Pain—Timolol—coronary artery disease	3.15e-05	0.000255	CcSEcCtD
Ponatinib—Nausea—Niacin—coronary artery disease	3.14e-05	0.000254	CcSEcCtD
Ponatinib—Rash—Telmisartan—coronary artery disease	3.13e-05	0.000253	CcSEcCtD
Ponatinib—Dermatitis—Telmisartan—coronary artery disease	3.13e-05	0.000253	CcSEcCtD
Ponatinib—Diarrhoea—Furosemide—coronary artery disease	3.12e-05	0.000252	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Lisinopril—coronary artery disease	3.11e-05	0.000252	CcSEcCtD
Ponatinib—Pruritus—Losartan—coronary artery disease	3.11e-05	0.000252	CcSEcCtD
Ponatinib—Headache—Telmisartan—coronary artery disease	3.11e-05	0.000252	CcSEcCtD
Ponatinib—Dizziness—Perindopril—coronary artery disease	3.1e-05	0.000251	CcSEcCtD
Ponatinib—Insomnia—Lisinopril—coronary artery disease	3.09e-05	0.00025	CcSEcCtD
Ponatinib—Nausea—Pravastatin—coronary artery disease	3.09e-05	0.00025	CcSEcCtD
Ponatinib—Gastrointestinal pain—Ramipril—coronary artery disease	3.08e-05	0.000249	CcSEcCtD
Ponatinib—Paraesthesia—Lisinopril—coronary artery disease	3.07e-05	0.000248	CcSEcCtD
Ponatinib—Vomiting—Captopril—coronary artery disease	3.07e-05	0.000248	CcSEcCtD
Ponatinib—Dyspnoea—Lisinopril—coronary artery disease	3.05e-05	0.000247	CcSEcCtD
Ponatinib—Rash—Captopril—coronary artery disease	3.04e-05	0.000246	CcSEcCtD
Ponatinib—Dermatitis—Captopril—coronary artery disease	3.04e-05	0.000246	CcSEcCtD
Ponatinib—Headache—Captopril—coronary artery disease	3.02e-05	0.000245	CcSEcCtD
Ponatinib—Gastrointestinal pain—Timolol—coronary artery disease	3.01e-05	0.000244	CcSEcCtD
Ponatinib—Dizziness—Furosemide—coronary artery disease	3.01e-05	0.000244	CcSEcCtD
Ponatinib—Dyspepsia—Lisinopril—coronary artery disease	3.01e-05	0.000243	CcSEcCtD
Ponatinib—Diarrhoea—Losartan—coronary artery disease	3.01e-05	0.000243	CcSEcCtD
Ponatinib—Nausea—Trandolapril—coronary artery disease	3e-05	0.000243	CcSEcCtD
Ponatinib—Nausea—Enalapril—coronary artery disease	2.99e-05	0.000242	CcSEcCtD
Ponatinib—Vomiting—Perindopril—coronary artery disease	2.98e-05	0.000241	CcSEcCtD
Ponatinib—Abdominal pain—Ramipril—coronary artery disease	2.98e-05	0.000241	CcSEcCtD
Ponatinib—Body temperature increased—Ramipril—coronary artery disease	2.98e-05	0.000241	CcSEcCtD
Ponatinib—Decreased appetite—Lisinopril—coronary artery disease	2.97e-05	0.00024	CcSEcCtD
Ponatinib—Rash—Perindopril—coronary artery disease	2.95e-05	0.000239	CcSEcCtD
Ponatinib—Dermatitis—Perindopril—coronary artery disease	2.95e-05	0.000239	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Lisinopril—coronary artery disease	2.95e-05	0.000239	CcSEcCtD
Ponatinib—Nausea—Telmisartan—coronary artery disease	2.95e-05	0.000239	CcSEcCtD
Ponatinib—Fatigue—Lisinopril—coronary artery disease	2.95e-05	0.000238	CcSEcCtD
Ponatinib—Headache—Perindopril—coronary artery disease	2.94e-05	0.000238	CcSEcCtD
Ponatinib—Pain—Lisinopril—coronary artery disease	2.92e-05	0.000236	CcSEcCtD
Ponatinib—Constipation—Lisinopril—coronary artery disease	2.92e-05	0.000236	CcSEcCtD
Ponatinib—Abdominal pain—Timolol—coronary artery disease	2.91e-05	0.000236	CcSEcCtD
Ponatinib—Body temperature increased—Timolol—coronary artery disease	2.91e-05	0.000236	CcSEcCtD
Ponatinib—Dizziness—Losartan—coronary artery disease	2.91e-05	0.000235	CcSEcCtD
Ponatinib—Vomiting—Furosemide—coronary artery disease	2.9e-05	0.000234	CcSEcCtD
Ponatinib—Rash—Furosemide—coronary artery disease	2.87e-05	0.000232	CcSEcCtD
Ponatinib—Dermatitis—Furosemide—coronary artery disease	2.87e-05	0.000232	CcSEcCtD
Ponatinib—Nausea—Captopril—coronary artery disease	2.87e-05	0.000232	CcSEcCtD
Ponatinib—Headache—Furosemide—coronary artery disease	2.85e-05	0.000231	CcSEcCtD
Ponatinib—Gastrointestinal pain—Lisinopril—coronary artery disease	2.79e-05	0.000226	CcSEcCtD
Ponatinib—Vomiting—Losartan—coronary artery disease	2.79e-05	0.000226	CcSEcCtD
Ponatinib—Nausea—Perindopril—coronary artery disease	2.78e-05	0.000225	CcSEcCtD
Ponatinib—Rash—Losartan—coronary artery disease	2.77e-05	0.000224	CcSEcCtD
Ponatinib—Dermatitis—Losartan—coronary artery disease	2.77e-05	0.000224	CcSEcCtD
Ponatinib—Headache—Losartan—coronary artery disease	2.75e-05	0.000223	CcSEcCtD
Ponatinib—Nausea—Furosemide—coronary artery disease	2.71e-05	0.000219	CcSEcCtD
Ponatinib—Asthenia—Ramipril—coronary artery disease	2.7e-05	0.000219	CcSEcCtD
Ponatinib—Abdominal pain—Lisinopril—coronary artery disease	2.7e-05	0.000219	CcSEcCtD
Ponatinib—Body temperature increased—Lisinopril—coronary artery disease	2.7e-05	0.000219	CcSEcCtD
Ponatinib—Pruritus—Ramipril—coronary artery disease	2.67e-05	0.000216	CcSEcCtD
Ponatinib—Asthenia—Timolol—coronary artery disease	2.64e-05	0.000214	CcSEcCtD
Ponatinib—Nausea—Losartan—coronary artery disease	2.61e-05	0.000211	CcSEcCtD
Ponatinib—Pruritus—Timolol—coronary artery disease	2.61e-05	0.000211	CcSEcCtD
Ponatinib—Diarrhoea—Ramipril—coronary artery disease	2.58e-05	0.000209	CcSEcCtD
Ponatinib—Diarrhoea—Timolol—coronary artery disease	2.52e-05	0.000204	CcSEcCtD
Ponatinib—Dizziness—Ramipril—coronary artery disease	2.49e-05	0.000202	CcSEcCtD
Ponatinib—Asthenia—Lisinopril—coronary artery disease	2.45e-05	0.000198	CcSEcCtD
Ponatinib—Dizziness—Timolol—coronary artery disease	2.44e-05	0.000197	CcSEcCtD
Ponatinib—Pruritus—Lisinopril—coronary artery disease	2.42e-05	0.000196	CcSEcCtD
Ponatinib—Vomiting—Ramipril—coronary artery disease	2.4e-05	0.000194	CcSEcCtD
Ponatinib—Rash—Ramipril—coronary artery disease	2.38e-05	0.000192	CcSEcCtD
Ponatinib—Dermatitis—Ramipril—coronary artery disease	2.37e-05	0.000192	CcSEcCtD
Ponatinib—Headache—Ramipril—coronary artery disease	2.36e-05	0.000191	CcSEcCtD
Ponatinib—Vomiting—Timolol—coronary artery disease	2.34e-05	0.00019	CcSEcCtD
Ponatinib—Diarrhoea—Lisinopril—coronary artery disease	2.34e-05	0.000189	CcSEcCtD
Ponatinib—Rash—Timolol—coronary artery disease	2.32e-05	0.000188	CcSEcCtD
Ponatinib—Dermatitis—Timolol—coronary artery disease	2.32e-05	0.000188	CcSEcCtD
Ponatinib—Headache—Timolol—coronary artery disease	2.31e-05	0.000187	CcSEcCtD
Ponatinib—Dizziness—Lisinopril—coronary artery disease	2.26e-05	0.000183	CcSEcCtD
Ponatinib—Nausea—Ramipril—coronary artery disease	2.24e-05	0.000181	CcSEcCtD
Ponatinib—Nausea—Timolol—coronary artery disease	2.19e-05	0.000177	CcSEcCtD
Ponatinib—Vomiting—Lisinopril—coronary artery disease	2.17e-05	0.000176	CcSEcCtD
Ponatinib—Rash—Lisinopril—coronary artery disease	2.16e-05	0.000174	CcSEcCtD
Ponatinib—Dermatitis—Lisinopril—coronary artery disease	2.15e-05	0.000174	CcSEcCtD
Ponatinib—Headache—Lisinopril—coronary artery disease	2.14e-05	0.000173	CcSEcCtD
Ponatinib—Nausea—Lisinopril—coronary artery disease	2.03e-05	0.000164	CcSEcCtD
Ponatinib—LCK—Signaling Pathways—POMC—coronary artery disease	6.79e-07	5.41e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CREB1—coronary artery disease	6.79e-07	5.41e-06	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—IL6—coronary artery disease	6.79e-07	5.41e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CCND1—coronary artery disease	6.79e-07	5.4e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—LPL—coronary artery disease	6.78e-07	5.4e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CCND1—coronary artery disease	6.77e-07	5.39e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—AGT—coronary artery disease	6.7e-07	5.33e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—ESR1—coronary artery disease	6.68e-07	5.32e-06	CbGpPWpGaD
Ponatinib—KIT—Immune System—IL6—coronary artery disease	6.67e-07	5.31e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CCL2—coronary artery disease	6.65e-07	5.29e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL6R—coronary artery disease	6.63e-07	5.28e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—GPX1—coronary artery disease	6.62e-07	5.27e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—FN1—coronary artery disease	6.6e-07	5.26e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—F2—coronary artery disease	6.6e-07	5.26e-06	CbGpPWpGaD
Ponatinib—FGFR1—Disease—PIK3CA—coronary artery disease	6.6e-07	5.26e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MMP9—coronary artery disease	6.59e-07	5.25e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—PIK3CA—coronary artery disease	6.58e-07	5.24e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL6ST—coronary artery disease	6.57e-07	5.23e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MMP9—coronary artery disease	6.57e-07	5.23e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—APOE—coronary artery disease	6.56e-07	5.23e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GSTP1—coronary artery disease	6.55e-07	5.22e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IGF1—coronary artery disease	6.53e-07	5.2e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—VCAN—coronary artery disease	6.53e-07	5.2e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NFKBIA—coronary artery disease	6.52e-07	5.19e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PPARGC1A—coronary artery disease	6.49e-07	5.17e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—APOA1—coronary artery disease	6.49e-07	5.17e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ALDOA—coronary artery disease	6.48e-07	5.16e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—HMOX1—coronary artery disease	6.46e-07	5.14e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CD36—coronary artery disease	6.44e-07	5.13e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CXCL8—coronary artery disease	6.41e-07	5.1e-06	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—AKT1—coronary artery disease	6.4e-07	5.1e-06	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—IL6—coronary artery disease	6.39e-07	5.08e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CAT—coronary artery disease	6.37e-07	5.08e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PPP2CA—coronary artery disease	6.36e-07	5.07e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—VEGFA—coronary artery disease	6.35e-07	5.06e-06	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—IL6—coronary artery disease	6.33e-07	5.04e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—KIT—coronary artery disease	6.32e-07	5.03e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—IL6—coronary artery disease	6.31e-07	5.03e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—DCN—coronary artery disease	6.29e-07	5.01e-06	CbGpPWpGaD
Ponatinib—LYN—Immune System—PIK3CA—coronary artery disease	6.29e-07	5.01e-06	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—PIK3CA—coronary artery disease	6.28e-07	5e-06	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PTGS2—coronary artery disease	6.28e-07	5e-06	CbGpPWpGaD
Ponatinib—FGFR2—Disease—IL6—coronary artery disease	6.27e-07	4.99e-06	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—AKT1—coronary artery disease	6.27e-07	4.99e-06	CbGpPWpGaD
Ponatinib—ABL1—Immune System—PIK3CA—coronary artery disease	6.26e-07	4.98e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—VEGFA—coronary artery disease	6.24e-07	4.96e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—SERPINE1—coronary artery disease	6.2e-07	4.94e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—APOB—coronary artery disease	6.19e-07	4.93e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GSTP1—coronary artery disease	6.17e-07	4.91e-06	CbGpPWpGaD
Ponatinib—KIT—Disease—IL6—coronary artery disease	6.16e-07	4.9e-06	CbGpPWpGaD
Ponatinib—KIT—Immune System—AKT1—coronary artery disease	6.15e-07	4.9e-06	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—AKT1—coronary artery disease	6.15e-07	4.89e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CASP3—coronary artery disease	6.14e-07	4.89e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ALDH2—coronary artery disease	6.12e-07	4.87e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PPARGC1A—coronary artery disease	6.12e-07	4.87e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—MTHFR—coronary artery disease	6.11e-07	4.86e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—HMOX1—coronary artery disease	6.09e-07	4.85e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—GSK3B—coronary artery disease	6.06e-07	4.83e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GSTM1—coronary artery disease	6.02e-07	4.79e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—POMC—coronary artery disease	6.01e-07	4.79e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CREB1—coronary artery disease	6.01e-07	4.79e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CAT—coronary artery disease	6.01e-07	4.78e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—FGF2—coronary artery disease	6.01e-07	4.78e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CCND1—coronary artery disease	5.97e-07	4.76e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—LIPC—coronary artery disease	5.97e-07	4.75e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—HBA1—coronary artery disease	5.97e-07	4.75e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3C2A—coronary artery disease	5.97e-07	4.75e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP2C19—coronary artery disease	5.97e-07	4.75e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—MAPK1—coronary artery disease	5.94e-07	4.73e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—APOC3—coronary artery disease	5.93e-07	4.72e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NOS3—coronary artery disease	5.92e-07	4.72e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—VEGFA—coronary artery disease	5.92e-07	4.71e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—LPL—coronary artery disease	5.91e-07	4.7e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—VEGFA—coronary artery disease	5.9e-07	4.7e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—LDLR—coronary artery disease	5.89e-07	4.69e-06	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—AKT1—coronary artery disease	5.89e-07	4.69e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CCL2—coronary artery disease	5.88e-07	4.68e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL6R—coronary artery disease	5.87e-07	4.67e-06	CbGpPWpGaD
Ponatinib—FGFR1—Disease—IL6—coronary artery disease	5.85e-07	4.65e-06	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—PIK3CA—coronary artery disease	5.84e-07	4.65e-06	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—AKT1—coronary artery disease	5.84e-07	4.65e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—APOB—coronary artery disease	5.83e-07	4.64e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—IL6—coronary artery disease	5.83e-07	4.64e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TGFB1—coronary artery disease	5.83e-07	4.64e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—AKT1—coronary artery disease	5.83e-07	4.64e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—SLC9A1—coronary artery disease	5.82e-07	4.64e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GSTT1—coronary artery disease	5.82e-07	4.64e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—AGT—coronary artery disease	5.8e-07	4.62e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MMP9—coronary artery disease	5.8e-07	4.62e-06	CbGpPWpGaD
Ponatinib—FGFR2—Disease—AKT1—coronary artery disease	5.79e-07	4.61e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IGF1—coronary artery disease	5.78e-07	4.61e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GPX1—coronary artery disease	5.76e-07	4.59e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—JAK2—coronary artery disease	5.76e-07	4.58e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GCLC—coronary artery disease	5.76e-07	4.58e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CETP—coronary artery disease	5.76e-07	4.58e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TGFB1—coronary artery disease	5.72e-07	4.56e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PPARG—coronary artery disease	5.72e-07	4.55e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MAPK1—coronary artery disease	5.72e-07	4.55e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—SDC1—coronary artery disease	5.69e-07	4.53e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—APOE—coronary artery disease	5.69e-07	4.53e-06	CbGpPWpGaD
Ponatinib—KIT—Disease—AKT1—coronary artery disease	5.68e-07	4.52e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GSTM1—coronary artery disease	5.67e-07	4.52e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—POMC—coronary artery disease	5.64e-07	4.49e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—APOA1—coronary artery disease	5.62e-07	4.47e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CD36—coronary artery disease	5.61e-07	4.47e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MAPK1—coronary artery disease	5.61e-07	4.47e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—TGFB1—coronary artery disease	5.59e-07	4.45e-06	CbGpPWpGaD
Ponatinib—LYN—Immune System—IL6—coronary artery disease	5.57e-07	4.43e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—LPL—coronary artery disease	5.57e-07	4.43e-06	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—IL6—coronary artery disease	5.56e-07	4.43e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PPP2CA—coronary artery disease	5.54e-07	4.41e-06	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IL6—coronary artery disease	5.54e-07	4.41e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—SERPINE1—coronary artery disease	5.49e-07	4.37e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—MAPK1—coronary artery disease	5.49e-07	4.37e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GPX1—coronary artery disease	5.43e-07	4.33e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TGFB1—coronary artery disease	5.43e-07	4.32e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TGFB1—coronary artery disease	5.42e-07	4.31e-06	CbGpPWpGaD
Ponatinib—FGFR1—Disease—AKT1—coronary artery disease	5.39e-07	4.29e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	5.38e-07	4.28e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—AKT1—coronary artery disease	5.38e-07	4.28e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PSMB5—coronary artery disease	5.38e-07	4.28e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PSMA6—coronary artery disease	5.38e-07	4.28e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MAPK1—coronary artery disease	5.33e-07	4.24e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—MTHFR—coronary artery disease	5.32e-07	4.24e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—FGF2—coronary artery disease	5.32e-07	4.23e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MAPK1—coronary artery disease	5.31e-07	4.23e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CD36—coronary artery disease	5.29e-07	4.21e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—MAPK1—coronary artery disease	5.26e-07	4.19e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CXCL8—coronary artery disease	5.25e-07	4.18e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CTGF—coronary artery disease	5.25e-07	4.18e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NOS3—coronary artery disease	5.24e-07	4.18e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PPP2CA—coronary artery disease	5.22e-07	4.16e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—VEGFA—coronary artery disease	5.21e-07	4.15e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GOT2—coronary artery disease	5.21e-07	4.14e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—HMGCR—coronary artery disease	5.21e-07	4.14e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—PIK3CA—coronary artery disease	5.16e-07	4.1e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—ALB—coronary artery disease	5.14e-07	4.09e-06	CbGpPWpGaD
Ponatinib—LYN—Immune System—AKT1—coronary artery disease	5.14e-07	4.09e-06	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—AKT1—coronary artery disease	5.13e-07	4.09e-06	CbGpPWpGaD
Ponatinib—ABL1—Immune System—AKT1—coronary artery disease	5.11e-07	4.07e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—JAK2—coronary artery disease	5.1e-07	4.06e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—AGT—coronary artery disease	5.05e-07	4.02e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CASP3—coronary artery disease	5.03e-07	4e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—MTHFR—coronary artery disease	5.01e-07	3.99e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—PIK3CA—coronary artery disease	4.96e-07	3.95e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—APOE—coronary artery disease	4.95e-07	3.94e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—TGFB1—coronary artery disease	4.95e-07	3.94e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PPARG—coronary artery disease	4.95e-07	3.94e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—NOS3—coronary artery disease	4.92e-07	3.92e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—APOA1—coronary artery disease	4.9e-07	3.9e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CCND1—coronary artery disease	4.9e-07	3.9e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—POMC—coronary artery disease	4.88e-07	3.89e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—PIK3CA—coronary artery disease	4.87e-07	3.88e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—MAPK1—coronary artery disease	4.86e-07	3.87e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PLCB1—coronary artery disease	4.79e-07	3.81e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TGFB1—coronary artery disease	4.78e-07	3.8e-06	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—AKT1—coronary artery disease	4.77e-07	3.8e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—AGT—coronary artery disease	4.76e-07	3.79e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—PIK3CA—coronary artery disease	4.76e-07	3.79e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MMP9—coronary artery disease	4.75e-07	3.78e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MAPK1—coronary artery disease	4.69e-07	3.73e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—APOE—coronary artery disease	4.67e-07	3.72e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CXCL8—coronary artery disease	4.65e-07	3.7e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ABCA1—coronary artery disease	4.64e-07	3.69e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—PIK3CA—coronary artery disease	4.62e-07	3.68e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—APOA1—coronary artery disease	4.61e-07	3.67e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—PIK3CA—coronary artery disease	4.61e-07	3.67e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL6—coronary artery disease	4.57e-07	3.63e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—PIK3CA—coronary artery disease	4.56e-07	3.63e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PTGS2—coronary artery disease	4.5e-07	3.58e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GGT1—coronary artery disease	4.49e-07	3.58e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GOT1—coronary artery disease	4.49e-07	3.58e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—ALB—coronary artery disease	4.45e-07	3.55e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CASP3—coronary artery disease	4.45e-07	3.54e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IL6—coronary artery disease	4.39e-07	3.5e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CCND1—coronary artery disease	4.33e-07	3.45e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PPARG—coronary artery disease	4.31e-07	3.43e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IL6—coronary artery disease	4.31e-07	3.43e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—VEGFA—coronary artery disease	4.27e-07	3.4e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—NOS3—coronary artery disease	4.26e-07	3.39e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—POMC—coronary artery disease	4.25e-07	3.39e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—IL6—coronary artery disease	4.22e-07	3.36e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—PIK3CA—coronary artery disease	4.21e-07	3.36e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—AKT1—coronary artery disease	4.21e-07	3.35e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MMP9—coronary artery disease	4.21e-07	3.35e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IL6—coronary artery disease	4.09e-07	3.26e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IL6—coronary artery disease	4.08e-07	3.25e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—PIK3CA—coronary artery disease	4.07e-07	3.24e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PPARG—coronary artery disease	4.07e-07	3.24e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—AKT1—coronary artery disease	4.05e-07	3.23e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL6—coronary artery disease	4.04e-07	3.22e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GSTP1—coronary artery disease	4.04e-07	3.21e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—POMC—coronary artery disease	4.01e-07	3.19e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PPARGC1A—coronary artery disease	4e-07	3.18e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—HMOX1—coronary artery disease	3.98e-07	3.17e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—AKT1—coronary artery disease	3.98e-07	3.17e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CAT—coronary artery disease	3.93e-07	3.13e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TGFB1—coronary artery disease	3.92e-07	3.12e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PTGS2—coronary artery disease	3.9e-07	3.1e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—AKT1—coronary artery disease	3.89e-07	3.1e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—ALB—coronary artery disease	3.88e-07	3.09e-06	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PIK3CA—coronary artery disease	3.86e-07	3.07e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MAPK1—coronary artery disease	3.84e-07	3.06e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—APOB—coronary artery disease	3.81e-07	3.04e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—VEGFA—coronary artery disease	3.78e-07	3.01e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—AKT1—coronary artery disease	3.78e-07	3.01e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—AKT1—coronary artery disease	3.77e-07	3e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—IL6—coronary artery disease	3.73e-07	2.97e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—AKT1—coronary artery disease	3.73e-07	2.97e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—NOS3—coronary artery disease	3.71e-07	2.95e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GSTM1—coronary artery disease	3.71e-07	2.95e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ALB—coronary artery disease	3.66e-07	2.91e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—LPL—coronary artery disease	3.64e-07	2.9e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IL6—coronary artery disease	3.6e-07	2.87e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GPX1—coronary artery disease	3.55e-07	2.83e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—NOS3—coronary artery disease	3.5e-07	2.78e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TGFB1—coronary artery disease	3.47e-07	2.76e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CD36—coronary artery disease	3.46e-07	2.75e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—AKT1—coronary artery disease	3.44e-07	2.74e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PPP2CA—coronary artery disease	3.42e-07	2.72e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MAPK1—coronary artery disease	3.4e-07	2.71e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PTGS2—coronary artery disease	3.39e-07	2.7e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PIK3CA—coronary artery disease	3.33e-07	2.65e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—AKT1—coronary artery disease	3.32e-07	2.65e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—MTHFR—coronary artery disease	3.28e-07	2.61e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PTGS2—coronary artery disease	3.2e-07	2.55e-06	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—AKT1—coronary artery disease	3.15e-07	2.51e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—AGT—coronary artery disease	3.11e-07	2.48e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—APOE—coronary artery disease	3.05e-07	2.43e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—APOA1—coronary artery disease	3.02e-07	2.4e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL6—coronary artery disease	2.95e-07	2.35e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PIK3CA—coronary artery disease	2.95e-07	2.35e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3CA—coronary artery disease	2.77e-07	2.2e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—AKT1—coronary artery disease	2.72e-07	2.17e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PPARG—coronary artery disease	2.66e-07	2.12e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—POMC—coronary artery disease	2.62e-07	2.09e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL6—coronary artery disease	2.61e-07	2.08e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—AKT1—coronary artery disease	2.41e-07	1.92e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CA—coronary artery disease	2.4e-07	1.91e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ALB—coronary artery disease	2.39e-07	1.9e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—NOS3—coronary artery disease	2.29e-07	1.82e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—AKT1—coronary artery disease	2.26e-07	1.8e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PTGS2—coronary artery disease	2.09e-07	1.66e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CA—coronary artery disease	2.09e-07	1.66e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CA—coronary artery disease	1.97e-07	1.57e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—AKT1—coronary artery disease	1.96e-07	1.56e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—AKT1—coronary artery disease	1.71e-07	1.36e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—AKT1—coronary artery disease	1.61e-07	1.28e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CA—coronary artery disease	1.29e-07	1.02e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—AKT1—coronary artery disease	1.05e-07	8.37e-07	CbGpPWpGaD
